Mobile Phone-Based Video Directly Observed Therapy for Tuberculosis

结核病手机视频直观治疗

基本信息

  • 批准号:
    7878280
  • 负责人:
  • 金额:
    $ 23.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): An estimated one-third of the world's population is infected with M. tuberculosis, resulting in 9.2 million cases of tuberculosis (TB) and 2.2 million deaths annually. Without good compliance with treatment regimens lasting =6 months, illness progresses, patients remain contagious, and mutations form rendering the bacteria resistant to anti-TB medications. So great are the individual and community level impacts of poor adherence that health agencies worldwide recommend that, whenever feasible, patients should be observed taking each dose of medication, referred to as directly observed therapy (DOT). However, DOT is resource intensive, restrictive to patients, and unavailable to patients who live far from DOT providers. The purpose of this study is to develop and pilot test a flexible and cost-effective method of providing remote DOT via video cellular phones, which patients will use to video themselves taking their medications and transfer the videos to DOT workers for review. Advantages of video cell phone DOT (VCP-DOT) include the fact that videos can be taken from any location at any time and DOT workers can manage larger case loads by reviewing videos at their convenience. Our long term goal is to provide TB control programs in developed and developing countries with improved methods of effectively treating TB. The aims of this Exploratory/Developmental R21 research study are to; 1) identify modifiable barriers and facilitators to VCP-DOT delivery among patients and providers; 2) determine the acceptability and feasibility of VCP-DOT and estimate treatment adherence rates compared to in-person DOT; and 3) characterize patient experiences with VCP-DOT to identify program components that could impact adherence and patient satisfaction. We hypothesize that VCP-DOT is acceptable to patients and achieves greater treatment adherence at a lower cost than in-person DOT. To address these aims we will conduct a series of focus groups to identify facilitators and barriers to VCP-DOT elicited from TB healthcare providers and patients. Focus groups will first be conducted in San Diego to identify major themes, and then in Tijuana to identify cultural and setting-specific differences. This information will be used to fine-tune the intervention before it is pilot tested among 40 patients in San Diego and 10 patients in Tijuana to assess its feasibility, acceptability, cost and potential efficacy compared to existing DOT programs. The pilot might also reveal technical strengths and weaknesses of the intervention. Findings will be used to propose a sufficiently powered randomized controlled trial to test the efficacy and cost-effectiveness of VCP-DOT in international settings. This study will take place in the US/Mexico border cities of San Diego and Tijuana, because their high TB incidence rates and close proximity allow us to cost-effectively develop and pilot test VCP-DOT in two areas with vastly different TB control systems. If effective, VCP-DOT could dramatically reduce the burden and cost of TB treatment to patients and their providers, thereby increasing treatment adherence and expanding treatment options globally including among patients who live beyond the reach of in-person DOT. PUBLIC HEALTH RELEVANCE: Until TB treatment duration is significantly reduced from the current 6-plus months, novel methods are needed to cost-effectively assure high levels of treatment adherence to cure the patient and avoid development of anti- TB drug resistance. This Exploratory/Developmental study will evaluate the use of video-camera cell phones to deliver directly observed TB therapy. This study is responsive to the U.S. Federal TB Task Force's recommendation for "identifying alternatives and adjuncts to currently used treatment protocols through behavioral research to improve adherence to therapy (domestic and international)".
描述(由申请人提供):估计世界上三分之一的人口感染了M。结核病,每年导致920万例结核病(TB)和220万例死亡。如果没有持续6个月以上的治疗方案的良好依从性,疾病就会进展,患者仍然具有传染性,并形成突变,使细菌对抗结核药物产生耐药性。依从性差对个人和社区的影响如此之大,以至于世界各地的卫生机构建议,只要可行,就应该观察患者服用每一剂药物,称为直接观察治疗(DOT)。然而,DOT是资源密集型的,对患者有限制,并且对于远离DOT提供者的患者不可用。本研究的目的是开发和试点测试一种灵活和具有成本效益的方法,通过视频手机提供远程DOT,患者将使用视频自己服用药物,并将视频传输给DOT工作人员进行审查。视频手机DOT(VCP-DOT)的优点包括可以在任何时间从任何地点拍摄视频,DOT工作人员可以通过在方便时查看视频来管理更大的案件负载。我们的长期目标是为发达国家和发展中国家的结核病控制项目提供有效治疗结核病的改进方法。本探索性/开发性R21研究的目的是:1)确定患者和提供者中VCP-DOT输送的可修改障碍和促进因素; 2)确定VCP-DOT的可接受性和可行性,并估计与面对面DOT相比的治疗依从率; 3)描述患者使用VCP-DOT的经历,以确定可能影响依从性和患者满意度的计划组成部分。我们假设,VCP-DOT是可以接受的患者,并实现更大的治疗依从性,以较低的成本比在人的DOT。为了实现这些目标,我们将进行一系列的焦点小组,以确定从结核病医疗服务提供者和患者中引出的VCP-DOT的促进因素和障碍。焦点小组将首先在圣地亚哥进行,以确定主要主题,然后在蒂华纳,以确定文化和环境的具体差异。这些信息将被用来微调干预之前,它是试点测试40名患者在圣地亚哥和10名患者在蒂华纳,以评估其可行性,可接受性,成本和潜在的疗效相比,现有的DOT计划。试点还可能揭示干预措施的技术优势和弱点。研究结果将用于提出一项充分把握度的随机对照试验,以测试VCP-DOT在国际环境中的疗效和成本效益。这项研究将在美国/墨西哥边境城市圣地亚哥和蒂华纳进行,因为它们的结核病发病率高,距离近,使我们能够在结核病控制系统截然不同的两个地区以成本效益高的方式开发和试点测试VCP-DOT。如果有效,VCP-DOT可以大大减少患者及其提供者的结核病治疗负担和成本,从而提高治疗依从性并在全球范围内扩大治疗选择,包括那些生活在现场DOT范围之外的患者。 公共卫生相关性:在TB治疗持续时间从目前的6个多月显著减少之前,需要新的方法来成本有效地确保高水平的治疗依从性以治愈患者并避免抗TB药物耐药性的发展。这项探索性/开发性研究将评价使用摄像手机提供直接观察的结核病治疗。本研究响应了美国联邦结核病工作组的建议,即“通过行为研究确定目前使用的治疗方案的替代方案和替代方案,以提高对治疗的依从性(国内和国际)"。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard S Garfein其他文献

Richard S Garfein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard S Garfein', 18)}}的其他基金

Rapid Detection of TB from Blood using Cell-Free DNA and CRISPR
使用无细胞 DNA 和 CRISPR 快速检测血液中的结核病
  • 批准号:
    10620065
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
A Novel Point-of-Care Assay for Diagnosing TB from Blood using Exosomes
使用外泌体从血液中诊断结核病的新型护理点检测
  • 批准号:
    10596302
  • 财政年份:
    2022
  • 资助金额:
    $ 23.47万
  • 项目类别:
Cell Phone Video Directly Observed Therapy to Monitor Short Course LTBI Treatment
手机视频直接观察治疗监测短期 LTBI 治疗
  • 批准号:
    8848622
  • 财政年份:
    2015
  • 资助金额:
    $ 23.47万
  • 项目类别:
Cell Phone Video Directly Observed Therapy to Monitor Short Course LTBI Treatment
手机视频直接观察治疗监测短期 LTBI 治疗
  • 批准号:
    9221964
  • 财政年份:
    2015
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8452218
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8477164
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8662547
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8304207
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8141202
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
墨西哥毒品旅游:墨西哥新毒品法对美国注射吸毒者 HIV-HCV-TB 的影响
  • 批准号:
    8685629
  • 财政年份:
    2011
  • 资助金额:
    $ 23.47万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 23.47万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了